CD38 a biomarker and therapeutic target in non-hematopoietic tumors.

Susana G Barrientos-RobledoJorge A Cebada-RuizJuan Carlos Rodriguez-Alba Shantal Lizbeth Baltierra-UribeMaria A Díaz Y OreaHéctor Romero-Ramírez

Published in: Biomarkers in medicine (2022)

The type II transmembrane glycoprotein CD38 has recently been implicated in regulating metabolism and the pathogenesis of multiple conditions, including aging, inflammation and cancer. CD38 is overexpressed in several tumor cells and microenvironment tumoral cells, associated to migration, angiogenesis, cell invasion and progression of the disease. Thus, CD38 has been used as a progression marker for different cancer types as well as in immunotherapy. This review focuses on describing the involvement of CD38 in various non-hematopoietic cancers.

Keyphrases

papillary thyroid
nk cells
stem cells
bone marrow
oxidative stress
induced apoptosis
squamous cell
signaling pathway
vascular endothelial growth factor